Analyst consensus rating
Generate Biomedicines Analyst Rating: Strong Buy
GENB is rated Strong Buy by 5 analysts with a $25.60 target. As of 2026-08-26.
Direct answer
Generate Biomedicines's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.60.
Forecast evidence checked August 26, 2026.
Get free Generate Biomedicines email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.14
- Average price target
- $25.60
- High price target
- $30.00
- Low price target
- $22.00
- Low target gap
- +36.3%
- Target upside
- +58.6%
- High target gap
- +85.9%
- Target range width
- 49.6%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Generate Biomedicines?
Generate Biomedicines has a verified Strong Buy consensus. The same dataset has an average price target of $25.60.
How far are Generate Biomedicines's low and high targets from the recorded price?
The low target implies +36.3%, while the high target implies +85.9%.
How many analysts are included in Generate Biomedicines's consensus?
The verified consensus includes 5 analysts.
How is Generate Biomedicines's target upside or downside calculated?
The average target of $25.60 is divided by the recorded price of $16.14, then one is subtracted to produce +58.6%. This does not guarantee a future return.
When was Generate Biomedicines's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.